Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. by Lei, K. I. et al.
Br. J. Cancer (1994). 70, 1009 1013
1994
Serious pulmonary complications in patients receiving recombinant
granulocyte colony-stimulating factor during BACOP chemotherapy for
aggressive non-Hodgkin's lymphoma
K.I.K. Lei, W.T. Leung & P.J. Johnson
The Department ofClinical Oncologs, Chinese UniversitY ofHong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong.
Summanr Four of 12 Chinese patients receiving BACOP. in combination with recombinant human
granulocyte colony-stimulating factor. for aggressive non-Hodgkin's lymphoma developed a rapidly progres-
sive pneumonic illness characterised by diffuse pulmonary infiltrates and hypoxaemia. The condition proved
fatal in three. and in none could an infective cause be identified. A retrospective analysis revealed only one
episode of pneumonia in the previous 24 patients in whom the same BACOP regimen was administered
without granulocvte colony-stimulating factor support. Granulocyte colony-stimulating factor, by augmenting
white cell production. pulmonary sequestration and margination and production of toxic oxygen species. may
exacerbate underlying subclinical bleomycin pulmonary toxicity. Caution should be exercised before using
granulocyte-stimulating factors in bleomycin-containing regimens.
Myelosuppression is the major factor contributing to infec-
tion. mortality, morbidity and dose reduction in patients
receiving cytotoxic chemotherapy (Pizzo. 1984, Pizzo &
Meyers, 1989). Recombinant human granulocyte colony-
stimulating factor (G-CSF) has been demonstrated to
stimulate the proliferation and differentiation of neutrophils
and to be a clinically useful drug (Morstyn et al., 1988;
Gabrilove et al., 1988a,b; Yoshida et al.. 1990). Accelerated
recovery from neutropenia and reduction in associated neut-
ropenic febrile and infective episodes have been documented
(Morstyn et al., 1988; Sheridan et al., 1989; Bronchud et al.,
1987, 1988; Pettengell et al., 1992). G-CSF has been well
tolerated in most clinical trials and has not, until recently,
been associated with serious adverse effects (Neidhart et al.,
1989; Lindeman et al.. 1989).
Recently, however, there have been three bnref reports
suggesting that G-CSF may augment cytotoxic drug-induced
pulmonary toxicity (Boogaerts et al., 1993; Iki et al., 1993;
Matthews, 1993). This has prompted us to describe our own
experience in Chinese patients receiving the BACOP regimen
for aggressive non-Hodgkin's lymphoma, during which we
also encountered an unexpectedly high incidence of serious
pulmonary complications. In order to assess the possible role
of G-CSF more accurately, we compared the current series
with the 24 of our previous patients receiving the same
regimen without G-CSF support.
Patients and metKods
Twelve Chinese patients (seven men and five women), median
age 45 years (range 24-64 years), with histologically
confirmed aggressive non-Hodgkin's lymphoma (NHL)
received induction chemotherapy in combination with G-CSF
between September 1991 and October 1992. None had
documented pulmonary disease or any form of anti-cancer
therapy before receiving this treatment. The chemotherapy
regimen was BACOP, administered every 28 days for six
courses: bleomycin 5mgm- intravenously on days 15 and
22, doxorubicin 25 mgm-2 intravenously on days 1 and 8,
cyclophosphamide 650 mg m-- intravenously on days 1 and
8, vincristine 1.4 mg m-- intravenously on days I and 8 and
prednisone 60 mg m-2 orally from days 15 to 28. The G-CSF
was administered once daily subcutaneously, S .Lg kg- from
day 5 to day 19 (excepting day 8) during each course of
chemotherapy. For the purpose of this analysis, pneumonia
was defined as an acute condition characterised by fever,
dyspnoea, cough with or without sputum production and
consolidation changes or airspace shadowing apparent on the
chest radiographs. The diagnosis of respiratory failure was
made when there was an acute hypoxaemia with
Pao, <8 kPa (60 mmHg) or ventilatory failure with
Paco.> 7 kPa (55 mmHg).
The case records of NHL patients receiving BACOP were
reviewed and the incidence of febrile episodes (oral
temperature greater than 38'C), leucopenic episodes (white
cell count less than 1 x l0 1'-), pulmonary complications
and associated fatal events occurring during induction
chemotherapy was recorded. The characteristics of the group
receiving G-CSF were then compared with a 'control group'
comprising 24 consecutive patients with aggressive NHL who
received the same BACOP therapy for three or more courses
between January 1989 and August 1991, the period
immediately before G-CSF was introduced into our practice.
Statistical analysis was performed by Wilcoxon test and
Fisher's exact test (corrected for small group sample) as
appropriate.
Results
There were 12 patients in the G-CSF group who received
BACOP in combination with G-CSF and 24 patients in the
control group who received BACOP alone. The clinical
characteristics of these two groups are set out in Table I.
There were no significant differences between the two groups
in terms of sex, age, Karnofsky performance status and stage
of disease.
Amount ofchemotherapy received and remission rate
As summarised in Table I, the median number of courses of
BACOP received by each patient was 4.5 (range 1-6) in the
G-CSF group and 5 (range 3-6) in the control group. How-
ever, the total dose of bleomycin received by each patient
was significantly lower in the G-CSF group (median 54.5 mg,
range 28-108 mg) than in the control group (median 85 mg,
range 40-108 mg). Of the 12 patients in the G-CSF group,
seven (58%) achieved complete remission and two (17%)
died early in the induction chemotherapy before scheduled
assessment. Of the 24 patients in the control group, 17 (71%)
achieved complete remission and one (4%) died before
reassessment.
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Table I Comparison of the clinical characteristics, number of courses of chemotherapy
rgunen. cumulative dose of bleomycin and response rate of patients with aggressive
non-Hodgkin's lymphoma in G-CSF group and historical control group (***P<0.05)
G-CSF group Control group
Number of patients
Sex
Male
Age (years)
Median (range)
Karnofsky performance status
Median (range)
Stage
IV III III
Unknown
Number of courses of treatment
Median (range)
Cumulative dose of bleomycin (mg)***
Median (range)
Disease status'
CR
Unknown
12
7 (58%)
45 (24-64)
24
16 (66%)
37 (28-74)
100 (90-100) 100 (80-100)
4
3
3
2
0
(33%)
(25%)
(25%)
(17%)
(0%)
4.5 (1-6)
54.5 (28- 108)
7 (58%)
2 (17%)
16
4
2
1
(67%)
(17%)
(4%)
(8%)
(4%)
5 (3-6)
85 (40-108)
17 (71%)
1 (4%)
'Disease status after the last course of chemotherapy. CR, complete remission.
Incidence ofcomplications during induction chemotherapy
The incidence of fever, leucopenia, pneumonia, respiratory
failure and death from pneumonia and median nadir white
cell count during the first and second courses of treatment
(nadir I and nadir II) are shown in Table II. The number of
febnrle episodes in the G-CSF group was 11 (92%), which
was significantly higher than the control group 14 (58%).
Leucopenic episodes in the G-CSF and control groups occur-
red in 9 and 22 patients respectively. There was no significant
difference in the incidence of leucopenia between the G-CSF
and the control groups. The median white cell nadir I and
nadir II were 4.3 x 1091-l (range 0.5-9.5 x 109) and
2.8 x 1091-' (range 0.6-12.2 x 1091-') respectively in the G-
CSF group compared with 1.5 x 1091-l (range 0.6-5 x
10091-') and 2 x 1091-l (range 0.8-8.4 x 1091-1) in the con-
trol group. The incidence of pneumonia, respiratory failure
and death from pneumonia [4(33%), 3(25%) and 3 (25%)
respectively] in the G-CSF group was significantly higher
than in the control group, in which there was only a single
case of pneumonia (4%) and no episodes of respiratory
failure or related deaths were recorded (Table II).
Case report of the three fatal cases
Patient 1 was a 41-year-old man who received BACOP and
G-CSF for stage IIA aggressive Non-Hodgkin's lymphoma
diagnosed in November 1991. He achieved complete remis-
sion after two courses of treatment. After completing his
third course of treatment, he developed fever, chills, a pro-
ductive cough and dyspnoea. On examination, he had central
cyanosis with marked tachypnoea and diffuse crepitations in
his chest. The white cell count was 6.9 x 109 1-1, and arterial
blood gases showed respiratory failure with Pao2 = 6.0 kPa
(on 50% inspired oxygen). The chest radiograph revealed
diffuse opacities with pneumonic changes and a ground-glass
appearance in both lung fields (Figure 1). Broad-spectrum
antibiotics were started but his condition progressed.
Repeated cultures, bronchoalveolar lavage and serology were
all negative. Lung biopsy only showed bronchiolitis
obliterans and organised pneumonia. Despite 2 months'
intensive care, ventilatory support and aggressive anti-
microbial, antifungal and antiviral treatment, his condition
deteriorated. The terminal event was acute gastrointestinal
haemorrhage.
Table II Incidence of fever, leucopenia and pulmonary
complications during induction chemotherapy (*P<0.05)
G-CSF group Control group
Number of patients 12 24
Fever episodes* 11 14
Leucopenia episodes 9 22
Nadir I. median (range) x 09l -'* 4.3 1.5
Nadir 11, median (range) x 109- 1 2.8 2
Pneumonia* 4 1
Respiratory failure* 3 0
Death from pneumonia* 3 0
Patient II was a 61-year-old woman with stage IV aggres-
sive NHL diagnosed in December 1991. She received BACOP
and G-CSF treatment and achieved complete remission after
the first course. On day 8 of the third course of treatment,
she presented with a 2 day history of fever and increasing
dyspnoea. Examination revealed widespread crepitations. Her
white cell count on admission was 28.6 x 1091-'. Arterial
blood gases showed respiratory failure with Pao, = 4.79 kPa.
The chest radiograph showed diffuse consolidation with an
air bronchogram and a small left pleural effusion (Figure 2).
She was treated with the broad-spectrum antibiotics, co-
trimoxazole and amphotericin. However, subsequent chest
radiographs showed progressive consolidation. None of the
cultures was positive. She continued to deteriorate and died
of progressive pneumonia and respiratory failure 6 days after
admission.
Patient III was a 47-year-old woman with a history of
Sjogren's syndrome since 1985. She developed stage IIE ag-
gressive non-Hodgkin's lymphoma in both parotid glands in
September 1992, and was treated with BACOP and G-CSF.
After day 15 of the second course of treatment, she presented
with a 1 day history of fever, mild dyspnoea and occasional
cough. On examination her chest was clear. Her WBC was
2.8 x 1091-' but the chest radiograph showed ill-defined
opacities in both lung bases. She was treated with broad-
spectrum antibiotics, but deteriorated rapidly with increasing
dyspnoea and cyanosis. A chest radiograph at this stage
showed widespread alveolar opacities with air bronchogram
(Figure 3). Her white cell count was 20.3 x 10 1-' and
arterial blood gases showed respiratory failure with Pao, =
4.79 kPa (on 51 min-' inspired oxygen). BronchoscopicEXACERBATION OF DRUG-INDUCED PULMONARY TOXICITY BY G-CSF 1011
Fige 1 Chest radiograph obtained on admission, showing Fuge 3 Chest radiograph obtained 3 days after admission.
diffuse alveolar opacities with pneumonic changes and ground- showing diffuse alveolar infiltration with air bronchogram. and
glass appearance (nipple markers in place and artifacts superim- Hickman's catheter in situ.
posed on fifth and eighth ribs in left lung field).
examination was normal. All cultures and bronchoavelolar
lavage were negative. She did not respond to antibiotics and
cotrimoxazole and died of severe pneumonia 7 days after
admission.
Discas
In the first report of the use of BACOP in patients with
non-Hodgkin's lymphoma. Skarin et al. (1977) described the
development of pulmonary infiltrates in 21 73 (29%) of their
patients, and three patients died from pulmonary insuffici-
ency. More recently 23% of patients receiving m-BACOD in
a large controlled clinical trial comparing this regimen with
CHOP were also reported to have developed mild, severe or
life-threatening pulmonary toxicity, characterised by pul-
monary infiltrates and hypoxaemia (Shapiro et al., 1991). The
cause of this syndrome remains unknown. In the studies
mentioned above no infective agent could be identified des-
pite intensive investigation including transbronchial and open
biopsy. and indeed this was our expenrence. Gordon et al.
(1992) suggested that either methotrexate or bleomycin might
be involved, although the latter seemed to be implicated less
frequently (Bauer et al., 1983). Methotrexate was not a com-
ponent of the original BACOP regimen which, as already
noted, was associated with a high rate of pulmonary compli-
cations, and it has been suggested that the pulmonary toxi-
city of bleomycin is enhanced by combination with other
drugs (Bauer et al., 1983; Shapiro et al., 1991). The risk of
bleomycin-induced pulmonary toxicity increases significantly
at a cumulative dose greater than 500 units (Ginsberg et al.,
1982). In several of Skarin et al.'s patients, in whom the dose
of bleomycin was 15 mgm'2, the pulmonary infiltrates were
Figwe 2 Chest radiograph obtained on admission, showing attributed to bleomycin toxicity. The total bleomycin dose
diffuse consolidation with air bronchogram and alveolar prior to lung toxicity was 72 mg in reversible cases and 93 mg
infiltrates, left pleural effusion and Hickman's catheter in situ. in fatal cases (Skarin et al., 1977). The total cumulative dose1012 KI.K. LEI et al.
of bleomycin in our G-CSF group (median 54.5 mg) was well
below the reported toxic level, and also significantly lower
than in the historical control (median 85 mg).
The pulmonary toxicity of bleomycin has been attributed
to production of reactive oxygen species which damage the
pulmonary epithelium and stimulate influx of peripheral
polymorphonuclear cells (Kreisman & Wolkove, 1992). It is
possible that recombinant G-CSF exacerbates this pheno-
menon by virtue of its actions of increasing the number of
neutrophils and enhancing superoxide (0,-) release from
neutrophils in response to stimuli (Ohsaka et al., 1989;
Tanimura et al.. 1992). It also rapidly increases the expres-
sion of adhesion-related molecule C3bi receptors on neutro-
phils. which together with increased neutrophil count may
predispose to neutrophil aggregation in blood vessels
(Ohsaka et al.. 1989). Furthermore, G-CSF has been shown
to induce a transient neutropenia, which may be related to
tissue migration and,or increased adherence of neutrophils to
endothelium (Bronchud et al.. 1988; Morstyn et al., 1989).
Consistent with this suggestion. Matthews (1993) reported a
possible synergistic effect of G-CSF on bleomycin-induced
pulmonary toxicity. describing increased pulmonary toxicity
among patients receiving combination G-CSF and ABVD
chemotherapy in Hodgkin's disease, which was characterised
by cough. dyspnoea. fatigue, pulmonary infiltrates and
impaired pulmonary function. Similarly. Boogaerts et al.
(1993) also reported an adult respiratory distress syndrome
(ARDS) in three out of eight patients receiving G-CSF
therapy for drug-induced agranulocytosis, which was charac-
terised by severe respiratory distress, rapid development of
diffuse pulmonary infiltrates and severe hypoxaemia.
In the light of these observations it is possible that, in our
patients, G-CSF may have caused endothelial damage by
stimulating white cell production. pulmonary sequestration
and margination of phagocytes with release of superoxide,
and thereby exacerbated bleomycin-initiated subclinical lung
damage. This possibility is supported by analysis of our
historical control group who did not receive G-CSF and did
not develop any undue pulmonary complications. It also
finds support from a recent report from Japan describing
eight cases of drug-induced pneumonia among 40 patients
with malignant lymphoma receiving G-CSF in combination
with various cytotoxic regimens. By comparison, this group
also saw no such complication among 40 similar patients
who did not receive G-CSF (Iki et al., 1993). The possibility
of an ethnic difference in susceptibility to G-CSF must also
be considered. However, other Chinese patients with non-
Hodgkin's lymphoma treated with G-CSF and CHOP have
not experienced any unexpected pulmonary complications (R.
Liang, personal communication).
We cannot exclude the possibility that unidentified
pathogens may have been involved. The clinical course was
so rapid as to exclude open lung biopsy and pulmonary
function studies in most cases, and autopsy is seldom agreed
to in our population. Similarly. clustering of patients with the
well-recognised pulmonary complication of BACOP may
have been coincidental in the G-CSF group. However, we
believe our data are sufficiently striking to counsel caution
before using G-CSF in combination with bleomycin. The
move away from BACOP in favour of older regimens such as
CHOP may render this problem less likely in the future.
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